The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria
Open accessAbstract
Rationale: In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and/or traction bronchiectasis plus reticulation, without atypical features of usual interstitial pneumonia (UIP), on high-resolution computed tomography (HRCT). Thus, the patients in these trials represented patients with definite UIP and a large subgroup of patients with possible UIP. Objectives: To investigate the potential impact of diagnostic subgroups on the progression of IPF and the effect of nintedanib. Methods: We conducted a post hoc subgroup analysis of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy versus patients without either, using pooled data from the INPULSIS trials. Measurements and Main Results: Seven hundred twenty-three (68.1%) patients had honeycombing and/or biopsy, and 338 (31.9%) patients had no honeycombing or biopsy. In these subgroups, respectively, the adjusted annual rate of decline in FVC in patients treated with placebo was −225.7 and −221.0 ml/yr, and the nintedanib versus placebo difference in the adjusted annual rate of decline in FVC was 117.0 ml/yr (95% confidence interval, 76.3–157.8) and 98.9 ml/yr (95% confidence interval, 36.4–161.5). There was no significant treatment-by-subgroup interaction (P = 0.8139). Adverse events were similar between the subgroups. Conclusions: Patients with IPF diagnosed in clinical practice who had possible UIP with traction bronchiectasis on HRCT and had not undergone surgical lung biopsy had disease that progressed in a similar way, and responded similarly to nintedanib, to that of patients with honeycombing on HRCT and/or confirmation of UIP by biopsy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [193]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationRaghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib is an intracellular inhibitor of tyrosine kinases (8) that has been approved for the treatment of IPF in several countries and regions, including the US (9), Europe (10), and Japan and that received a conditional recommendation for use in the latest international clinical practice guideline for the treatmen…”
Self-citationIdiopathic Interstitial Pneumonia: What Is the Effect of a Multidisciplinary Approach to Diagnosis?
Flaherty, K. R., King, T. E., Raghu, G., Lynch, J. P., Colby, T. V., Travis, W. D., Gross, B. H., Kazerooni, E. A., Toews, G. B., Long, Q., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200402-147oc · Cited by 673
Self-citationHigh-Resolution Computed Tomography in Idiopathic Pulmonary Fibrosis: Diagnosis and Prognosis
Lynch, D. A., Godwin, J. D., Safrin, S., Starko, K. M., Hormel, P., Brown, K. K., Raghu, G., King, T. E., Bradford, W. Z., Schwartz, D. A., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200412-1756oc · Cited by 547
Self-citationComorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review
Raghu, G., Amatto, V. C., Behr, J., & Stowasser, S. (2015) · European Respiratory Journal · doi:10.1183/13993003.02316-2014 · Cited by 463
Self-citationInterobserver Variability in the CT Assessment of Honeycombing in the Lungs
Watadani, T., Sakai, F., Johkoh, T., Noma, S., Akira, M., Fujimoto, K., Bankier, A. A., Lee, K. S., Müller, N. L., Song, J.-W., et al. (2013) · Radiology · doi:10.1148/radiol.12112516 · Cited by 411
Self-citationInterobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT
Walsh, S. L. F., Calandriello, L., Sverzellati, N., Wells, A. U., & Hansell, D. M. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207252 · Cited by 334
Self-citationPrevalence and prognosis of unclassifiable interstitial lung disease
Ryerson, C. J., Urbania, T. H., Richeldi, L., Mooney, J. J., Lee, J. S., Jones, K. D., Elicker, B. M., Koth, L. L., King, T. E., Wolters, P. J., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00131912 · Cited by 310
Self-citation
Research works printed but not linked: 1
- Raghu, 2015, Consistent effect of nintedanib on decline in FVC in patients across subgroups based on HRCT diagnostic criteria: results from the INPULSIS trials in IPF [abstract], Am J Respir Crit Care Med, 191, A1022
Cited by
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
Raghu, G., Remy-Jardin, M., Myers, J. L., Richeldi, L., Ryerson, C. J., Lederer, D. J., Behr, J., Cottin, V., Danoff, S. K., Morell, F., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201807-1255st · Cited by 4,103
Self-citationRaghu, G., Remy-Jardin, M., Richeldi, L., Thomson, C. C., Inoue, Y., Johkoh, T., Kreuter, M., Lynch, D. A., Maher, T. M., Martinez, F. J., et al. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0399st · Cited by 2,957
Self-citationRicheldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Self-citationMartinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Self-citationDiagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
Lynch, D. A., Sverzellati, N., Travis, W. D., Brown, K. K., Colby, T. V., Galvin, J. R., Goldin, J. G., Hansell, D. M., Inoue, Y., Johkoh, T., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30433-2 · Cited by 1,030
“8,9 The specific inclusion and exclusion criteria used in these studies have also highlighted the limitations of current diagnostic guidelines, and indicated opportunities for improvement.”
Self-citation
Metadata
- Authors
- Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M.
- Affiliations
- University of Washington (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- National Institute for Health and Care Research (GB)
- Michigan Medicine (US)
- Boehringer Ingelheim France S.A.S., Reims, France
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut
- Corresponding author
- Raghu, Ganesh
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-01-01
- Volume
- 195
- Issue
- 1
- Pages
- 78-85
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC5214917
- OpenAlex
- W2474839550
- Cited by
- 180
- References
- 20
- Citations by year
- 2025: 5 · 2024: 7 · 2023: 13 · 2022: 13 · 2021: 9 · 2020: 23 · 2019: 22 · 2018: 38 · 2017: 42
- FWCI
- 32.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, usual interstitial pneumonia, honeycombing, traction bronchiectasis, high-resolution computed tomography, lung biopsy, forced vital capacity decline, INPULSIS trials, treatment response, subgroup analysis
- MeSH terms
- Aged, Biopsy, Female, Humans, Indoles, Lung, Male, Protein-Tyrosine Kinases, Tomography, X-Ray Computed, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. https://app.cochat.ai/papers/10.1164/rccm.201602-0402oc
- The paper
- Raghu, G., Wells, A. U., Nicholson, A. G., Richeldi, L., Flaherty, K. R., Le Maulf, F., Stowasser, S., Schlenker-Herceg, R., & Hansell, D. M. (2017). Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201602-0402oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.